Aug 12, 2020
IDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update
May 15, 2020
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ/11 Tumors and Preclinical MAT2A Synthetic Lethality Program
May 13, 2020
Cardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
May 12, 2020
IDEAYA Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
Mar 18, 2020
IDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update
Mar 18, 2020
IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations
Mar 16, 2020
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States
Dec 09, 2019
IDE196 Program Updates: Targeting Initiation of Potentially Registration-Enabling Phase 2 Single-Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020
Nov 19, 2019
BerGenBio ASA: Results for the Third Quarter 2019
Sep 17, 2019
REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor
Jul 06, 2019
Array BioPharma Announces Interim Analysis Results from the BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer
May 07, 2019
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019
Feb 05, 2019
Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019
Jan 14, 2019
Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer
Oct 30, 2018
Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019
Oct 29, 2018
CStone announces first patient dosed in Phase I study in China for MEK inhibitor CS3006
Sep 25, 2018
Array BioPharma to Present at the 2018 Cantor Global Healthcare Conference
Sep 20, 2018
European Commission Approves BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) for Advanced BRAF-mutant Melanoma
Sep 13, 2018
Array BioPharma Announces Publication of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) Phase 3 Overall Survival Data in The Lancet Oncology
Aug 14, 2018
Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018